BTG and Mirada Medical Sign Three-Year Software Development Agreement

BTG and Mirada Medical Sign Three-Year Software Development Agreement

BTG and Mirada Medical Sign Three-Year Software Development Agreement

BTG plc (LSE: BTG), the global specialist healthcare company, has signed a three-year master service agreement with Mirada Medical Ltd, a global medical imaging software company.

Mirada and BTG began working together in October 2015 to develop software solutions to optimise radioembolisation therapy with TheraSphere®. That collaboration resulted in Simplicit90Y™, a customised, easy-to-use dosimetry software that helps physicians to personalise treatment with 90Y therapies, such as TheraSphere®, for patients with liver cancer. The Simplicit90Y™ software received CE Mark Certification in Europe in October 2016.

The agreement announced today includes projects to further enhance the Simplicit90Y™ product and to support BTG’s growing portfolio of interventional medicine products. The companies plan to leverage Mirada’s advanced digital image processing technology to improve workflow and ensure accurate and consistent use of BTG’s market leading products.

Peter Stratford, Chief Technology Officer at BTG, said “We are pleased to be strengthening our relationship with Mirada. The Symplicit90Y™ software has proven the value of their imaging software in personalising treatment for patients, and we’re excited to be developing additional features. We’re also eager to deliver a bespoke solution to support our broader portfolio. Advanced imaging technology is crucial in helping physicians optimally treat patients using our minimally invasive therapies.”

Hugh Bettesworth, Chief Executive of Mirada Medical, said “Collaborating with BTG, a recognised leader in interventional medicine, helps bring our intuitive software to more clinicians, and to improve outcomes for more patients. Our companies have a shared belief in the power of image processing to improve and personalise treatment for a wide range of minimally invasive procedures.”

About BTG Interventional Medicine
BTG Interventional Medicine is part of BTG plc, a global specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavors to do more than BTG to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of cancer, severe emphysema, severe blood clots, and varicose veins. To learn more about BTG Interventional Medicine, please visit:

About Mirada Medical Ltd
Mirada Medical is a leading international brand in medical imaging. The company develops advanced software applications which help healthcare professionals use medical images more effectively and efficiently to improve cancer care. Mirada’s products are used across diagnostic radiology, molecular imaging, radiation oncology, medical oncology, tumour board and elsewhere.

The company specialises in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention. Mirada’s advanced software products are available throughout the world under its own brand, and on an OEM basis through a select number of the world’s leading healthcare companies. To learn more about Mirada Medical, please visit:

For further information contact:

Chris Sampson, Corporate Communications Director
+44 20 7575 1595; Mobile: +44 7773 251 178

Mirada Medical Ltd
Annamaria Albano
+44(0)1865 261410:

Back to press releases